A $328M Bet That Epilepsy's Next Breakthrough Lives in the Hippocampus

What We Know (and Don't Know) From the Clinic

Rapport ran a Phase 2a proof-of-concept trial in adults with drug-resistant focal onset seizures. These weren't easy patients; they had implanted devices called RNS systems that continuously monitor brain activity, giving researchers an unusually detailed look at what the drug was doing.

Participants started at 0.75 mg per day for five days, then stepped up to 1.25 mg per day for eight weeks. An encouraging 86.7% of patients completed treatment, suggesting the drug was tolerable enough to stick with.

Rapport has described the topline results as positive, with post-hoc analyses showing early, consistent reductions in seizure severity. But full efficacy and safety data are still pending. That's a meaningful caveat: "positive topline" is a phrase companies love to use right up until the detailed numbers tell a more complicated story.

What we do know from Phase 1 is encouraging on the pharmacology side. RAP-219 achieved receptor occupancy exceeding the 50%–70% target range, has a long half-life of 8 to 14 days (meaning once-daily dosing should work), and showed no concerning signals on heart rhythms, vital signs, or lab tests. Its metabolism through a pathway called UGT1A4 also means low risk of drug-drug interactions, which matters enormously for epilepsy patients already juggling multiple medications.

Why China, Why Now

Tenacia isn't a random partner. The Shanghai-based company was founded in 2022 by Bain Capital specifically to build a CNS-focused platform in China. It's already commercial-stage, with a growing pipeline.

This is actually Tenacia's second major epilepsy licensing deal. Back in 2022, the company paid Marinus Pharmaceuticals $10 million upfront (with up to $256 million in milestones) for exclusive China rights to ganaxolone, a drug for rare seizure disorders. The Rapport deal follows the same playbook: find a differentiated CNS asset with solid early data, lock up Greater China rights, and add local clinical trial sites to accelerate the global program.

The timing is strategic. Rapport plans to start a global Phase 3 trial in Q2 2026, and Tenacia will contribute Chinese clinical sites to that effort. For Rapport, this means faster enrollment and a funded partner handling one of the world's largest pharmaceutical markets. For Tenacia, it means getting in early on a potential first-in-class drug before Phase 3 data either sends the price soaring or reveals problems.

A Broader Trend With Chinese Characteristics

This deal sits within a massive wave of cross-border licensing activity between Chinese and Western biotechs. The numbers are staggering: Chinese biotech out-licensing deals jumped from 42 in 2022 to 93 in 2025, with total upfront payments ballooning from $1.1 billion to $5.6 billion over the same period.

But there's a twist. Almost all of that action has been in oncology, antibody-drug conjugates, and obesity. CNS deals remain relatively rare, making the Rapport-Tenacia partnership something of an outlier. Analysts at Evaluate have noted that Chinese assets "aren't a bargain basement anymore," with average upfront payments per deal climbing to $172 million in 2025.

The $20 million upfront here is modest by comparison, which makes sense: RAP-219 is pre-Phase 3, and the Greater China territory alone doesn't command the same premium as global rights. But the $328 million total package signals that both sides see blockbuster potential if the drug delivers in pivotal trials.

The Competitive Race Nobody's Talking About

Rapport isn't alone in chasing TARPγ8. Janssen has its own compound, JNJ-55511118. Eli Lilly developed LY3130481. Both showed promising preclinical results with the same forebrain-selective profile.

The difference? RAP-219 appears to be the furthest along clinically. As of late 2024, no other TARPγ8-selective compound had publicly entered the clinic, giving Rapport a meaningful head start. That first-mover advantage is part of what makes the asset attractive to a partner like Tenacia.

Of course, being first doesn't guarantee being best. Phase 3 trials are where promising drugs go to face reality, and epilepsy trials are notoriously tricky: placebo response rates are high, patient populations are heterogeneous, and regulators want to see durable seizure reduction over months.

The Bottom Line

This deal is a bet on precision. Instead of carpet-bombing the brain's electrical system, RAP-219 aims to surgically quiet the regions where seizures begin. The science is elegant, the early data is encouraging, and the commercial logic (Rapport gets non-dilutive funding; Tenacia gets a potential first-in-class CNS asset in China) makes sense for both sides.

But $328 million in total deal value for a pre-Phase 3 asset in a single territory is a big number. Everything hinges on what happens when those pivotal trials read out. If RAP-219 proves it can stop seizures without the side-effect baggage of older drugs, this deal will look like a steal. If not, it'll be another expensive lesson in the gap between preclinical elegance and clinical reality.

Phase 3 kicks off in a matter of weeks. The clock is ticking.